Table 1 Mechanism of lentinan in inflammatory diseases
From: Lentinan progress in inflammatory diseases and tumor diseases
Type of disease | Model | Mechanism | in vivo /in vitro | Author, year |
|---|---|---|---|---|
IBD | Mouses models of colitis | Inhibit TLR4 pathway and NF‐κB Lower inflammatory cytokine IL-13 restore the structure of the intestinal microflora | In vivo,in vitro | Liu et al. 2017 [25] |
IBD | Mouses models of colitis | Downregulate TNFR1 to inhibit TNF-α-induced NF-κB activation and IL-8 | In vitro | Nishitani et al. 2013 [26] |
IBD | Mouses models of colitis | Stimulate of type 1 helper T cell immune responses | In vivo | Minato et al. 2023 [27] |
COVID-19 | Human airway epithelial cells | Reduce oxidative stress-induced apoptosis and reduce pro-inflammatory cytokine expression | In vitro | Murphy et al. 2020 [31] |
Influenza A viral | Mouses models influenza A viral | Regulate TLR4/MyD88 signaling pathway TNF-α, IL-1β, IL-4, IL-5, and IL-6 | In vivo,in vitro | Cui et al. 2022 [32] |
Chronic obstructive pulmonary | Human experiment | Lower adiponectin IL-17, D-dimer | In vivo | Sun et al. 2019 [33] |
Mastitis | Cell models of mastitis | Inhibiting NF-kB and MAPK | In vivo | Meng et al. 2022 [34] |
Skin diseases | Human immortalized keratinocytes | Reduce IL-8 and chemokine ligand-2 mRNA | In vivo | Zi et al. 2020 [36] |
Multiple sclerosis | Demyelination mouses models | Regulate dectin-1 receptors, TNF-α and IL-1β to promote the transformation of M1 cells into M2 cells | In vivo,in vitro | Zhang et al. 2020 [37] |
Enterogenic sepsis | Septic rats | Reduce the activation of TNF-α, IL-1β, IL-6 and regulate NF-κB signaling | In vivo,in vitro | Kuanget al, 2021 [41] |
Acute kidney injury | Septic rats | Reduce TNF-α, IL-1β, IL-6 | In vivo | Wang et al. 2016 [42] |
Burn sepsis | Septic rats | Inhibit Erk-FoxO10 signaling,reduced IL-10 | In vivo | Li et al. 2020 [44] |